Baseline demographics and clinical characteristics (cohort 2)
| Characteristic . | WG (n = 28) . | DG (n = 72) . | All treated patients (N = 100) . |
|---|---|---|---|
| Age, median (range), y | 67.0 (52-86) | 72.0 (35-95) | 71.0 (35-95) |
| ≥65 y, n (%) | 20 (71.4) | 52 (72.2) | 72 (72.0) |
| Male, n (%) | 12 (42.9) | 41 (56.9) | 53 (53.0) |
| Race, n (%) | |||
| White | 23 (82.1) | 60 (83.3) | 83 (83.0) |
| Other∗ | 5 (17.9) | 12 (16.7) | 17 (17.0) |
| ECOG PS score, n (%) | |||
| 0 | 15 (53.6) | 46 (63.9) | 61 (61.0) |
| 1 | 11 (39.3) | 23 (31.9) | 34 (34.0) |
| 2 | 2 (7.1) | 3 (4.2) | 5 (5.0) |
| MZL disease subtype, n (%) | |||
| Nodal | 6 (21.4) | 25 (34.7) | 31 (31.0) |
| Extranodal | 11 (39.3) | 23 (31.9) | 34 (34.0) |
| Splenic | 11 (39.3) | 24 (33.3) | 35 (35.0) |
| Ann Arbor staging, n (%) | |||
| I | 1 (3.6) | 6 (8.3) | 7 (7.0) |
| II | 3 (10.7) | 4 (5.6) | 7 (7.0) |
| III | 1 (3.6) | 7 (9.7) | 8 (8.0) |
| IV | 27 (78.6) | 52 (72.2) | 74 (74.0) |
| Unknown/missing† | 1 (3.6) | 3 (4.2) | 4 (4.0) |
| Time since diagnosis, median (range), y | 4.7 (0.3-20.1) | 4.4 (0.1-19.8) | 4.6 (0.1-20.1) |
| Number of prior treatments, median (range) | 1.0 (1-8) | 2.0 (1-5) | 2.0 (1-8) |
| Prior therapies, n (%) | |||
| Anti-CD20 mAb | 28 (100) | 72 (100) | 100 (100) |
| Chemotherapy | 19 (67.9) | 53 (73.6) | 72 (72.0) |
| Surgery/surgical procedures | 8 (28.6) | 11 (15.3) | 19 (19.0) |
| Radiation | 4 (14.3) | 7 (9.7) | 11 (11.0) |
| HSCT | 1 (3.6) | 3 (4.2) | 4 (4.0) |
| Status to most recent prior therapy, n (%) | |||
| Relapsed | 13 (46.4) | 33 (45.8) | 46 (46.0) |
| Refractory | 14 (50.0) | 35 (48.6) | 49 (49.0) |
| Unknown | 1 (3.6) | 4 (5.6) | 5 (5.0) |
| Characteristic . | WG (n = 28) . | DG (n = 72) . | All treated patients (N = 100) . |
|---|---|---|---|
| Age, median (range), y | 67.0 (52-86) | 72.0 (35-95) | 71.0 (35-95) |
| ≥65 y, n (%) | 20 (71.4) | 52 (72.2) | 72 (72.0) |
| Male, n (%) | 12 (42.9) | 41 (56.9) | 53 (53.0) |
| Race, n (%) | |||
| White | 23 (82.1) | 60 (83.3) | 83 (83.0) |
| Other∗ | 5 (17.9) | 12 (16.7) | 17 (17.0) |
| ECOG PS score, n (%) | |||
| 0 | 15 (53.6) | 46 (63.9) | 61 (61.0) |
| 1 | 11 (39.3) | 23 (31.9) | 34 (34.0) |
| 2 | 2 (7.1) | 3 (4.2) | 5 (5.0) |
| MZL disease subtype, n (%) | |||
| Nodal | 6 (21.4) | 25 (34.7) | 31 (31.0) |
| Extranodal | 11 (39.3) | 23 (31.9) | 34 (34.0) |
| Splenic | 11 (39.3) | 24 (33.3) | 35 (35.0) |
| Ann Arbor staging, n (%) | |||
| I | 1 (3.6) | 6 (8.3) | 7 (7.0) |
| II | 3 (10.7) | 4 (5.6) | 7 (7.0) |
| III | 1 (3.6) | 7 (9.7) | 8 (8.0) |
| IV | 27 (78.6) | 52 (72.2) | 74 (74.0) |
| Unknown/missing† | 1 (3.6) | 3 (4.2) | 4 (4.0) |
| Time since diagnosis, median (range), y | 4.7 (0.3-20.1) | 4.4 (0.1-19.8) | 4.6 (0.1-20.1) |
| Number of prior treatments, median (range) | 1.0 (1-8) | 2.0 (1-5) | 2.0 (1-8) |
| Prior therapies, n (%) | |||
| Anti-CD20 mAb | 28 (100) | 72 (100) | 100 (100) |
| Chemotherapy | 19 (67.9) | 53 (73.6) | 72 (72.0) |
| Surgery/surgical procedures | 8 (28.6) | 11 (15.3) | 19 (19.0) |
| Radiation | 4 (14.3) | 7 (9.7) | 11 (11.0) |
| HSCT | 1 (3.6) | 3 (4.2) | 4 (4.0) |
| Status to most recent prior therapy, n (%) | |||
| Relapsed | 13 (46.4) | 33 (45.8) | 46 (46.0) |
| Refractory | 14 (50.0) | 35 (48.6) | 49 (49.0) |
| Unknown | 1 (3.6) | 4 (5.6) | 5 (5.0) |